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There is increasing evidence that biomarkers of exhaled gases or exhaled breath condensate (EBC) may help in detecting
abnormalities in respiratory diseases mirroring increased, oxidative stress, airways inﬂammation and endothelial dysfunction.
Beside the traditional techniques to investigate biomarker proﬁles, “omics” sciences have raised interest in the clinical ﬁeld as
potentially improving disease phenotyping. In particular, metabonomics appears to be an important tool to gain qualitative and
quantitative information on low-molecular weight metabolites present in cells, tissues, and ﬂuids. Here, we review the potential
use of EBC as a suitable matrix for metabonomic studies using nuclear magnetic resonance (NMR) spectroscopy. By using this
approach in airway diseases, it is now possible to separate speciﬁc EBC proﬁles, with implication in disease phenotyping and
personalized therapy.
1.Introduction
Metabonomics is “the quantitative measurement of the
dynamic multiparametric metabolic response of living sys-
tems to pathophysiological stimuli or genetic modiﬁcation”
[1] due to any exposure (including drug administration),
lifestyle and environmental stress. It, therefore, appears to
be a powerful tool to monitor possible changes in metabolic
pathways, and measure the levels of biochemical molecules
generated in a living system. Metabolites are small molecules
with molecular mass ≤1kD [2] and are the end products
of cellular activity. Observation of changes in metabolite
concentrations may reveal the range of biochemical eﬀects
induced by a disease condition or its therapeutic interven-
tion. The metabonomic analysis has two major potential
applications, with implications in early diagnosis and disease
phenotyping.Itmayalsoallowtherecognitionofunexpected
or even unknown metabolites to formulate new patho-
physiological hypotheses [3]. Moreover, the identiﬁcation of
individual metabolic characteristics could predict personal
drug eﬀectiveness and/or toxicity [4, 5].
The application of metabonomic analysis in chronic
airway diseases has not been fully explored, but it holds a
valid background. Several airway diseases, such as asthma
or chronic obstructive pulmonary disease (COPD), which
are largely spread in the population, cannot be qualiﬁed
by a single biomarker and need a system biology analysis.
F u r t h e r m o r e ,o t h e ra i r w a yd i s e a s e ss u c ha sc y s t i cﬁ b r o s i s
(CF), although characterized by genetic abnormality, might
befruitfully investigated. Finally, therespiratory tract oﬀersa
natural matrix, theexhaled breath,which appearstobe note-
worthy for metabonomic analysis. Exhaled breath contains
many diﬀerent molecular species such as small inorganic
molecules like nitric oxide (NO) or carbon monoxide (CO),
volatileorganic compounds(VOCs),and soforth,[6],which
can be assayed in both the liquid and gaseous phases.
2.NMR-Metabonomics
The principal techniques used in metabonomics of breath
(“breathomics”) are mass spectrometry (MS) and nuclear
magnetic resonance (NMR) spectroscopy, since they can2 Journal of Biomedicine and Biotechnology
handle complex biological samples with a high sensitivity,
selectivity, and high throughput [7].
MS, usually combined with chromatographic separation
methods, separates the molecules of a sample on the basis of
their retention time and mass-to-charge ratio m/z, and their
representation in a spectrum [8, 9].
Real-time measurements of breath are also possible
using direct breathing ports and techniques such as proton
transfer reaction-mass spectrometry (PTR-MS), selected ion
ﬂow tube-mass spectrometry (SIFT-MS), and ion mobility
spectrometry (IMS), as well as other analytical techniques
including chemical sensors and various forms of laser
spectrometers [6]. MS metabonomics has recently been
applied to CF, where airway inﬂammation brings about an
increased production of reactive oxygen species, respon-
sible for degradation of cell membranes and causing the
formation of VOCs. Robroeks et al. [10]h a v ee v a l u a t e di f
VOCs metabonomics, analyzed by gas chromatography-time
of ﬂight-mass spectrometry to assess VOC proﬁles, could
discriminateCFandcontrols,andCFpatientswithandwith-
out Pseudomonas colonization. By using 22VOCs, a 100%
correct separation of CF patients and controls was possible,
while with 10VOCs, 92% of the subjects were correctly
classiﬁed. The reproducibility of VOC measurements with a
one-hourintervalwasverygood.Theauthorsconcludedthat
metabonomics of VOCs in exhaled breath was possible in a
reproducible way, and it was not only able to discriminate
between CF patients and controls, but also between CF
patients with or without Pseudomonas colonization.
NMR spectroscopy studies molecules by recording the
interaction of a radiofrequency electromagnetic radiation
with the nuclei (e.g., 1H, 13C, 15N, etc.) placed in a strong
magnetic ﬁeld. A single nucleus in a molecule can be
“observed” by monitoring the corresponding line (a “reso-
nance”) in an NMR spectrum, and the various parameters of
that line (frequency, splitting, linewidth and amplitude) can
be used to determine the molecular structure, conformation
and dynamics of the molecule. In principle, assignment (i.e.,
identiﬁcation) of NMR resonances for common metabolites
could be possible by comparing the observed chemical shifts
(i.e., the position of the line in a spectrum) with published
reference data. When dealing with metabolites of unknown
structure, chemical procedures for the separation of each
molecule and use of two-dimensional NMR experiments
(that spread signals in two dimensions) are required. Since
NMR spectra show hundred of resonances, the presence
of a discriminating element (e.g., a signal characteristic
of a speciﬁc metabolite) in a series of spectra is often
undetectablebyvisualinspectionduetotheinherentspectral
complexity generated by line overlapping, and it is better
highlighted by multivariate analysis (principal component
analysis, PCA), which carefully identiﬁes hidden phenomena
and trends in ensembles of spectra [11]. The application of
PCA to a group of spectra can immediately show whether
all spectra behave similarly grouping in a single class, or
fall apart into diﬀerent groups. The main advantage of
using NMR spectroscopy is its ability to provide a rapid
and accurate metabolic picture of the sample with minimal
sample pretreatment [12]. Furthermore, since the technique
is nondestructive, the samples can be investigated several
times as long as some preventative measures are taken to
avoid metabolite degradation.
3.Use ofNMR Metabonomicsfor
theStudyofAirways
Metabonomicshasbeenemployedtoinvestigateseveralbody
ﬂuids such as urine, plasma, serum, and tissue extracts as
well as in-vivo cells and their extracts [13], but only few
applications to airway diseases characterization have been
reported.
Airwayhyperreactivity (AHR),animportant characteris-
tic of airway pathophysiology in human asthma, has recently
been evaluated in an animal model of asthma exacerbation
by urine NMR-based metabonomics [14]. The authors
assumed that airway dysfunction and inﬂammation would
produce unique patterns of urine metabolites observed
by high-resolution proton (1H) NMR spectroscopy, and
the data analyzed by multivariate statistical analysis. In
this model, challenged (ovalbumin, administered intraperi-
toneally, plus ovalbumin aerosol) guinea pigs developed
AHR and increased inﬂammation compared with sensitized
or control animals. Partial least-squares discriminant anal-
ysis using concentration diﬀerences in metabolites could
discriminate challenged animals with 90% accuracy. Note-
worthy, urine metabonomic proﬁles were able to separate
not only sensitized from challenged and from na¨ ıve animals,
but also from animals treated with dexamethasone which
improvesAHR.Recently,Slupskyetal.demonstratedspeciﬁc
changes in NMR metabonomic urinary proﬁles during
episodes of pneumonia caused by Streptococcus pneumoniae
or Staphylococcus aureus [14].
NMR metabonomics was also used to study the mech-
anism behind the formation of airway bioﬁlm caused by
Pseudomonas aeruginosa, an infection particularly prevalent
in patients with CF [15]. In this kind of patients, the sessile
lifestyle, referred to as a bioﬁlm, allows the antibiotic resis-
tance and makes easier the process of colonization through
the synthesis of sticky, polymeric compounds. In contrast,
the planktonic, free-ﬂoating cells are more easily eradicated
with antibiotics. In this study, chemical diﬀerences between
planktonic and bioﬁlm cells, based on 1H-NMR, have been
reported. Inthisstudy,NMRtechniqueshavehighlightedthe
metabolic diﬀerences between the two modes of growth in
P. aeruginosa, and PCA, and spectral comparisons revealed
that the overall metabolism of planktonic and bioﬁlm cells
d i s p l a y e dm a r k e dd i ﬀerences, which require more extensive
NMR investigations.
More recently [16], metabolite proﬁles of bronchoalveo-
lar lavage ﬂuid (BALF) from pediatric patients with CF were
correlated to the degree of airway inﬂammation using NMR-
based metabonomics. BALF was collected from 11 children
with CF during clinically indicated bronchoscopy. The BALF
spectra with high levels of neutrophilic airway inﬂammation
displayed signals from numerous metabolites whereas the
spectra from subjects with low levels of inﬂammation were
verysparse. Themetabolitesidentiﬁedin samplestakenfrom
subjects with high inﬂammation include known markers ofJournal of Biomedicine and Biotechnology 3
inﬂammation such as amino acids and lactate, as well as
many novel signals. Statistical analysis highlighted the most
important metabolites that distinguished the high- from
the low-inﬂammation groups. This ﬁrst demonstration of
metabonomics of human BALF shows that clear distinctions
in the metabolic proﬁles can be observed between subjects
experiencing high versus low inﬂammation. However, the
bronchoalveolar lavage has the important limitation ofbeing
invasive, requiring the introduction of exogenous ﬂuid into
alveolar space.
4.EBC
EBC is a noninvasive method of sampling the airways; it can
be easily repeated and is acceptable to patients. Currently,
EBC is used to measure biomarkers of airway inﬂammation
and oxidative stress, and guidelines for its use have been
recently published [17]. EBC can also be considered a matrix
for analysis of environmental toxicants.
EBC collection requires the cooling of the exhaled breath
(Figure 1(a)), resulting in a ﬂuid sample that contains
evaporated and condensed particles (water, ammonia, etc.)
plus some droplets from the airway lining ﬂuid [17, 18].
These droplets are released by turbulent airﬂow and can be
added to the water vapor from anywhere between the alveoli
and the mouth. Therefore, not only volatiles, but also several
othermediatorswithnonvolatilecharacteristicscanbefound
in EBC samples, including adenosine, diﬀerent interleukins
(-4, -5, -8), interferon-γ [17]. EBC is mainly (>99%)
formed by water vapor, but also contains aerosol particles in
which several other biomolecules including leukotrienes, 8-
isoprostane,prostaglandins, hydrogenperoxide,nitricoxide-
derived products, and hydrogen ions, can be detected [17].
EBC markers of oxidative stress such as hydrogen peroxide,
isoprostanes, nitrogen oxides, pH, ammonia, prostanoids
and leukotrienes are increased in bronchial asthma [19].
EBC pH is lower in asthmatics and correlates well with
sputumeosinophilia,totalnitrate/nitrite,andoxidativestress
[20], but did not reﬂect the clinical status of the patients.
EBC markers that correlate with disease severity, response
to treatment, or both are hydrogen peroxide, leukotrienes,
8-isoprostane, nitrate, and nitrite [10]. It is assumed that
airway surface liquid becomes aerosolized during turbulent
airﬂowsothatthecontentofthecondensatereﬂectsthecom-
position of airway surface liquid, although large molecules
may not aerosolize as well as small soluble molecules.
The major advantage of EBC is represented by the
possibility to analyze both volatile and nonvolatile com-
pounds [21]. There are some recent approaches to compare
traditional blood test (glucose and urea) with the EBC
in metabolic diseases. Accordingly, glucose in EBC from
healthy volunteers was reproducible, unaﬀected by changes
in salivary glucose, and increased during experimental
hyperglycaemia [22].
Notably, EBC parameters are inﬂuenced by smoking,
alcohol consumption, equipment, exercise, mode and rate of
breathing, nasal contamination, environmental temperature
and humidity, and assays used [23, 24], leading to undesir-
ablevariability.Exogenouscontamination mayalso originate
from the oral cavity. Ammonia and sulfur-containing com-
pounds like H2S, methyl sulﬁde or mercaptans are released
from the oral cavity, being produced by bacteria from
diﬀerent oral niches. However, oral sterilization before
EBC collection or continuous saliva deglutition have been
suggested to limit the eﬀects of such contaminations [14].
The inﬂuence of age, sex, circadian rhythm, and infection
remains unknown. Thus the analysis of EBC currently has
important limitations.
Reference analytical techniques are required to provide
deﬁnitive evidence for the presence of some inﬂamma-
tory mediators in EBC and for their accurate quantitative
assessment in this biological ﬂuid. Finally, the physiological
meaning and biochemical origin of most of volatile com-
pounds are still not known, and biochemical pathways of
their generation, origin, and distribution are only partly
understood. Unfortunately, the concentrations of various
mediators studied are very low, requiring highly sensitive
assays.
5.Metabonomicsof EBCin
RespiratoryDiseases
NMR-based metabonomics can be used to analyze EBC
samples from adults, allowing a clear-cutseparation between
healthy subjects and patients with airway disease [11].
Although less sensitive than ELISA and MS, NMR spec-
troscopy requires minimal sample preparation with a rapid
acquisition time of spectra (10–15min). Furthermore, it
shows a high degree of sensitivity (≤ μmol/L), and is
nondestructive, allowing complete detection of metabolites
present in the sample (“sample metabolic ﬁngerprint”) at a
reasonable cost. NMR is also able to detect potential con-
tamination of EBC from saliva, and examine the interfering
eﬀect of residual external contaminants, which is crucial for
a correct EBC analysis of the variability of some biomarkers
[11, 25, 26].
To date there are several recommendations on the
methodological approach to EBC collection, but its stan-
dardization is not completely deﬁned, as EBC can be
contaminated by metabolites originating from saliva as well
as microbes present in the mouth [27, 28]. We have recently
proposed a possible protocol for EBC collection for NMR
purposes (Figure 1)[ 11]. It requires that subjects breath
through a mouthpiece and a two-way nonrebreathing valve,
which also serve as a saliva trap, at normal frequency and
tidal volume, while sitting comfortably and wearing a nose-
clip, for a period of 15 minutes (Figure 1(a)) [29]. They
maintained a dry mouth during collection by periodically
swallowing excess saliva. Condensate samples (1-2mL) are
immediately transferred into glass vials, closed with 20-mm
butylrubberlined withPTFE septa,and crimped with perfo-
rated aluminum seals. Volatile substances, possibly deriving
from extrapulmonary sources are removed by applying a
gentle stream of nitrogen for 3 minutes before sealing
[30, 31]. Nitrogen was used because concentrationofvolatile
solutes in EBC is dependent on their distribution between
the saliva, exhaled air, and droplets, and the condensate,
which can be altered by multiple factors including minute4 Journal of Biomedicine and Biotechnology
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Figure 1: Metabonomics of EBC using NMR. The exhaled breath is cooled in (a), then transferred into the NMR tube (0.5–0.7mL) (b) and
put in the spectrometer (c) to collect the spectra (d).
ventilation, salivary pH, solubility, temperature, and sample
preparation [29]. Therefore, spectral diﬀerencesmay depend
upon uncontrollable variables that prevent reliable quan-
tiﬁcation. The nitrogen stream also removes oxygen from
solutions, which, together with freezing of sealed samples
in liquid nitrogen, immediately “quenches” metabolism at
the collection time, and prevents any metabolic decay [32,
33]. Samples are then stored at −80◦C until NMR analysis.
Drying of the samples should be avoided to circumvent irre-
versible solute precipitation, and/or formation of insoluble
aggregates, which we observed upon dissolving the dried
condensate for NMR measurements.
Before NMR acquisition, EBC samples should be rapidly
defrosted and transferred into the NMR tube (Figure 1(b)).
To provide a ﬁeld frequency lock for NMR acquisition, 70μL
of a D2O solution [containing 1mM sodium 3-trimethylsilyl
[2,2,3,3-2H4] propionate (TSP) as a chemical shift and
concentration reference for 1H spectra, and sodium azide at
3mM] are added to 630μL of condensate reaching 700μLo f
total volume.
Following acquisition (Figures 1(c) and 1(d)), 1H-NMR
spectra are automatically data reduced to 200–250 integral
segments (“buckets”) using dedicated software packages
(e.g., AMIX, Bruker Biospin, Germany). The resulting
integrated regions are then used for statistical analysis
and pattern recognition. To avoid possible errors in signal
intensity due to diﬀerence in the volume of collected EBC
samples, before pattern recognition analysis each integral
region is normalized to the sum of all integral region of
each spectrum. In the presence of contaminant peaks (e.g.,
those originating from the condenser disinfectant), which
randomlyalterthetotalareaofthespectrum,eachbuckethas
to be normalized to the TSP peak of known concentration,
referring to a standard region comprised, for example,
between 0.014 and −0.014ppm.
Figure 2 represents spectra of saliva (left traces) and EBC
samples (right traces) from a healthy subject (HS, lower
spectra), a laryngectomized (middle spectra) and a COPD
(top spectra) subjects. A visual examination establishes a
striking correspondence between EBC spectra of HS and
laryngectomized, suggesting that potential oral contamina-
tion (e.g., bacteria and/or saliva) is undetectable and, if
present, beyond the sensitivity limit of NMR. By resorting to
literature data[34] and two-dimensional NMR experiments,
we identiﬁed all resonances present in EBC spectra (Fig-
ure 3). In saliva, signals between 3.3 and 6.0ppm originate
from carbohydrates [35] and these are virtually absent in
the EBC spectra (Figure 2). Compared to saliva, EBC spectra
present fewersignals, butbothsaliva and EBCspectra appear
to be diﬀerent among the HS, laryngectomized and COPD
classes considered (Figure 2); this is the basis for class
separation in PCA based on NMR data.
A recent study [11] has evaluated the capability of NMR
to separate EBC subjects with airway diseases (COPD) from
subjects without respiratory diseases. Based on qualitative
and quantitative spectral diﬀerences, ﬁve NMR signalsJournal of Biomedicine and Biotechnology 5
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Figure 2: Representative one-dimensional 1H-NMR spectra from
diﬀerent patients. Spectra of saliva (left traces) and EBC samples
(right traces) from a healthy (HS, lower traces), a laryngectomized
(middle spectra), and a COPD (top spectra) subject are reported.
Spectra were recorded on a Bruker Avance spectrometer operating
at a frequency of 600.13MHz (1H) and equipped with a TCI
CryoProbe. The water resonance was suppressed by using a speciﬁc
pulse sequence designed to avoidintensity alteration of signals.The
total acquisition time was ca. 10 minutes per sample. Spectra were
referred to TSP assumed to resonate at δ = 0.00ppm. In saliva
spectra, the group of signals centered at 3.8ppm originates from
carbohydrates, and is not visible in the corresponding EBC spectra.
appear to diﬀerentiate “respiratory” (COPD) from “non-
respiratory” (healthy and laryngectomized) subjects. It was
also clearly proved that saliva and condensate have diﬀerent
proﬁles, with saliva contamination showing little inﬂuence
on the interpretation of EBC by NMR-based metabonomics
[11].
Likewise, Carraro et al. [36] reported the acetate signal
variation as distinctive in asthmatic children with respect to
controls, concluding that acetate increase might be related
to increased acetylation of proinﬂammatory proteins in the
extracellular space in the airway environment. Whether the
metabonomic of exhaled breath condensate changes during
systemic or metabolic disease is currently unknown.
NMR-based metabonomic analyses of EBC could clearly
discriminate between asthmatic and healthy children, with
95% success rate in their classiﬁcation. Many authors
believe that asthma should no longer be considered a
single disease, and that eﬀorts should be made to identify
the diﬀerent biochemical and inﬂammatory proﬁles behind
asthma symptoms in order to treat them with speciﬁcally-
targetedtherapies[37].Montuschietal.[38]recentlyapplied
NMR-based metabonomics to discriminate between healthy
individuals, patients with stable CF,and cases of unstable CF,
showing that NMR is a powerful technique to monitor EBC
in CF.
In addition, we are currently applying NMR-based EBC
metabonomics in other genetic airway diseases such as
x32
17
15 14
13
12 11
16
(b)
(c)
(d)
(a) 10
9
8 3
1,2 4
5
6 7
ppm
8.5 7.5
ppm
4 3.5 3 2.5 2 1.5 1
1, 2 Leu + n-Butyrate
3 Propionate
4T h r
5L a c t a t e
6A l a
7n - B u t y r a t e
8A c e t a t e
9n - B u t y r a t e
10 Pyruvate
11 Succinate
12 Trimethylamine
13 Methanol
14 Ethanol
15 Lactate
16 Phe
17 Formate
Figure 3: Resonance assignments of representative 1H-NMR
spectra of EBC samples. The spectra of healthy (a), asthmatic (b),
steroid-treated asthmatic (c), and COPD (d) patients are depicted.
Peaks are labeled with progressive numbers, and assignments are
listed below.
primary ciliary dyskinesia, in light of the diﬀusion of fast
screening methods based on the exhaled NO on nasal or oral
breath.
6.Conclusions
The power of NMR-based metabonomics has been shown
for several bioﬂuids, including blood, urine, and saliva. We
believe that NMR metabonomics could also be applied to
EBC, which has the advantage of being noninvasive and
reproducible; furthermore it shows a distinctive proﬁle in
comparison to saliva, thus supporting its origin from lower
airways. Moreover, EBC metabonomic analysis is applied to
a living matrix in the absence of external induced pertur-
bations that may represent important preanalytical variable
with conventional assay measuring single compound.6 Journal of Biomedicine and Biotechnology
There is only limited experience with metabonomics on
EBC in humans, but reproducibility of method has been
successfully assessed, and useful protocols to diﬀerentiate
metabolic proﬁle of patients with asthma, COPD, or cystic
ﬁbrosis have been reported. However, more studies are
needed to show, if true, that the holistic approach of
EBC metabonomics may be a progress over the traditional
reductionistic approach in chronic airway disease.
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